Clinical Trial Search

Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543

Primary: Progression-free Survival at 6 Months — 6.5 percentage of participants

Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants

Primary: Death or Candidiasis — 31; 37 participants

Primary: Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population — -0.52; -0.33; -0.24; -0.34 Percent of Hemoglobin

Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score — 27.1 score on a scale

Primary: Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in…

Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001

Primary: Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR) — 3.0; 2.9; 3.1; 2.8 Scores on a scale

Primary: Localized Receiver Operating Characteristic (LROC) Comparison — 0.477; 0.536 unitless — p=<0.05

Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.82; -0.66 Percentage of HbA1c in the blood — p=<0.0001

Primary: Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline — 14.9; 10.1 Letters

Primary: CSF:Serum Ratio of Vancomycin — 0.08 ratio

Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 85020; 90030; 16220; 16120 (nanogram*hour) per milliliter (ng*h/mL)

Primary: Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth — 79.49…